CLARENCE RUNNELS: Open Payments
NPI 1487129649 · CARY, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$92,593 in 266 payments from 14 companies in 2025. Trend: 2023 $96,104 · 2024 $74,349 · 2025 $92,593
Speaker / faculty: $56,372Honoraria: $12,000Travel & lodging: $10,694Consulting: $8,813Food & beverage: $4,714
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 91 | $42,034 |
| Neurocrine BioSciences, Inc. | 35 | $22,708 |
| Axsome Therapeutics, Inc. | 42 | $13,520 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $13,095 |
| Supernus Pharmaceuticals, Inc. | 34 | $435 |
| Alkermes, Inc. | 19 | $366 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| IDORSIA PHARMACEUTICALS US INC | 3 | $82 |
| Teva Pharmaceuticals USA, Inc. | 4 | $79 |
| Bausch Health US, LLC | 3 | $57 |
Products named: VRAYLAR, INGREZZA, Auvelity, CAPLYTA, Qelbree, ARISTADA, REXULTI, Quviviq.
Industry payments across NC — which companies pay providers there.
